Recurrence of ROP After Anti-VEGF Treatment
This chapter is about recurrence of ROP after anti-VEGF treatment. The clinical course and timing of recurrence after anti-VEGF treatment is clarified. Furthermore, major clinical studies about the incidence of recurrence after anti-VEGF treatment for ROP are summarized.
KeywordsRecurrence of ROP Anti-VEGF Recurrence ROP
- 1.Darwish D, Chee RI, Patel SN, Jonas K, Ostmo S, Campbell JP, Chiang MF, Chan RVP. Anti-Vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity. Asia Pac J Ophthalmol (Phila). 2018;7:136–44.Google Scholar
- 6.Wallace DK, Dean TW, Hartnett ME, Kong L, Smith LE, Hubbard GB, McGregor ML, Jordan CO, Mantagos IS, Bell EF, Kraker RT, Pediatric Eye Disease Investigator Group. A dosing study of Bevacizumab for retinopathy of prematurity: late recurrences and additional treatments. Ophthalmology. 2018;7 https://doi.org/10.1016/j.ophtha.2018.05.001.CrossRefGoogle Scholar
- 9.Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, Ehrt O, Aisenbrey S, Roider J, Gerding H, Jandeck C, Smith LEH, Walz JM, Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (CARE-ROP) Study Group. Comparing alternative Ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr. 2018;172:278–86.CrossRefGoogle Scholar